$FBLG
FibroBiologics, Inc. Stock $fblg

$fblg Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224030603 Filed on August 07, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.139M	$2.249M	$2.490M
YoY Change	44.82%	-32.6%
% of Gross Profit
Research & Development	$1.213M	$975.0K	$960.0K
YoY Change	111.32%	-4.51%	100.84%
% of Gross Profit
Depreciation & Amortization	$38.00K	$37.00K	$35.00K
YoY Change	192.31%	1133.33%	3400.0%
% of Gross Profit
Operating Expenses	$3.352M	$3.224M	$3.450M
YoY Change	63.43%	-26.02%	52.32%
Operating Profit	-$3.352M	-$3.224M	-$3.450M
YoY Change	63.35%	54.04%	52.32%
Interest Expense	$74.00K	$5.000K	$4.000K
YoY Change		-103.42%	-97.04%
% of Operating Profit
Other Income/Expense, Net	$2.852M	$30.00K
YoY Change	-2122.7%	-141.67%
Pretax Income	-$500.0K	$898.0K	-$8.460M
YoY Change	-77.19%	-119.62%
Income Tax
% Of Pretax Income
Net Earnings	-$500.0K	$898.0K	-$8.460M
YoY Change	-77.19%	-112.56%	250.31%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01	$0.03	-$0.27
Diluted Earnings Per Share	-$0.01	$0.03	-$0.27
COMMON SHARES
Basic Shares Outstanding	35.16M shares	32.72M shares	32.63M shares
Diluted Shares Outstanding	33.52M shares	32.72M shares	31.13M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.827M	$5.973M	$8.158M
YoY Change	-27.3%	-47.5%
Cash & Equivalents	$7.827M	$5.973M	$8.158M
Short-Term Investments
Other Short-Term Assets	$18.00K	$18.00K	$18.00K
YoY Change	-87.84%	-95.29%
Inventory
Prepaid Expenses	$353.0K	$518.0K	$746.0K
Receivables
Other Receivables
Total Short-Term Assets	$8.198M	$6.509M	$8.922M
YoY Change	-24.89%	-44.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$772.0K	$799.0K	$770.0K
YoY Change	-67.63%	-61.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.271M	$2.403M	$2.477M
YoY Change	-4.78%	15.31%
TOTAL ASSETS
Total Short-Term Assets	$8.198M	$6.509M	$8.922M
Total Long-Term Assets	$2.271M	$2.403M	$2.477M
Total Assets	$10.47M	$8.912M	$11.40M
YoY Change	-21.28%	-35.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.179M	$1.208M	$814.0K
YoY Change	43.78%	102.01%
Accrued Expenses	$392.0K	$382.0K	$372.0K
YoY Change	11.05%	11.05%
Deferred Revenue	$241.0K	$1.500M
YoY Change
Short-Term Debt	$115.0K	$287.0K	$459.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.677M	$10.13M	$13.99M
YoY Change	408.14%	975.58%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.055M	$1.167M	$1.277M
YoY Change	-27.09%	-24.66%
Total Long-Term Liabilities	$1.055M	$1.167M	$1.277M
YoY Change		-24.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.677M	$10.13M	$13.99M
Total Long-Term Liabilities	$1.055M	$1.167M	$1.277M
Total Liabilities	$7.732M	$11.30M	$15.26M
YoY Change	180.04%	353.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$32.42M	-$31.92M	-$32.82M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.737M	-$2.387M	-$3.863M
YoY Change
Total Liabilities & Shareholders Equity	$10.47M	$8.912M	$11.40M
YoY Change	-21.28%	-35.63%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$500.0K	$898.0K	-$8.460M
YoY Change	-77.19%	-112.56%	250.31%
Depreciation, Depletion And Amortization	$38.00K	$37.00K	$35.00K
YoY Change	192.31%	1133.33%	3400.0%
Cash From Operating Activities	-$2.606M	-$1.947M	-$4.275M
YoY Change	128.8%	-46.82%	109.97%
INVESTING ACTIVITIES
Capital Expenditures	$11.00K	$66.00K	$8.000K
YoY Change	-97.34%	-17.5%	-85.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$11.00K	-$66.00K	-$8.000K
YoY Change	-97.34%	-17.5%	-85.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.471M	-172.0K	$3.278M
YoY Change	375.64%	-101.34%	-77.5%
NET CHANGE
Cash From Operating Activities	-2.606M	-1.947M	-$4.275M
Cash From Investing Activities	-11.00K	-66.00K	-$8.000K
Cash From Financing Activities	4.471M	-172.0K	$3.278M
Net Change In Cash	1.854M	-2.185M	-$1.005M
YoY Change	-402.94%	-123.98%	-108.06%
FREE CASH FLOW
Cash From Operating Activities	-$2.606M	-$1.947M	-$4.275M
Capital Expenditures	$11.00K	$66.00K	$8.000K
Free Cash Flow	-$2.617M	-$2.013M	-$4.283M
YoY Change	68.62%	-46.19%	104.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument		usd
	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument		usd
	FBLG	Fair Value Adjustment Of Forward Contract Liability FairValueAdjustmentOfForwardContractLiability		usd
CY2024Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts		usd
CY2023Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts		usd
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts		usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2024Q2	FBLG	Deemed Dividend DeemedDividend		usd
CY2023Q2	FBLG	Deemed Dividend DeemedDividend		usd
	FBLG	Deemed Dividend DeemedDividend		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2024Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument		usd
	FBLG	Fair Value Adjustment Of Forward Contract Liability FairValueAdjustmentOfForwardContractLiability		usd
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	FBLG	Increase Decrease In In Commitment Fee Payable IncreaseDecreaseInInCommitmentFeePayable		usd
	FBLG	Increase Decrease In Payable To Parent IncreaseDecreaseInPayableToParent		usd
	FBLG	Rofn Agreement Payments To Parent RofnAgreementPaymentsToParent		usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
	FBLG	Proceeds From Issuance Of Preferred Stock And Preference Stock1 ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	FBLG	Issuance Of Series B Preferred Stock For Conversion Of Notes And Accrued Interest IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest		usd
	FBLG	Reclassification Of Derivative Liability For Conversion Of Notes To Series B Preferred Stock ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock		usd
CY2024Q2	FBLG	Deemed Dividend DeemedDividend		usd
CY2023Q2	FBLG	Deemed Dividend DeemedDividend		usd
	FBLG	Deemed Dividend DeemedDividend		usd
CY2024Q2	FBLG	Liability Instrument Fair Value LiabilityInstrumentFairValue		usd
CY2024Q2	FBLG	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree		usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	29532000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25609000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31919000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24357000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-2387000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1253000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8912000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11821000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	975000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	547000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1935000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1021000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2249000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1546000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4739000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3337000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	3224000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2093000	usd
	us-gaap	Operating Expenses OperatingExpenses	6674000	usd
	us-gaap	Operating Expenses OperatingExpenses	4358000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3224000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2093000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6674000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4358000	usd
CY2024Q2	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument	-5527000	usd
	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument	-2422000	usd
CY2024Q2	FBLG	Fair Value Adjustment Of Forward Contract Liability FairValueAdjustmentOfForwardContractLiability	1500000	usd
	FBLG	Fair Value Adjustment Of Forward Contract Liability FairValueAdjustmentOfForwardContractLiability	1500000	usd
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	1941000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-57000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-72000	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	70000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	110000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	5000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	10000	usd
	us-gaap	Interest Expense InterestExpense	9000	usd
	us-gaap	Interest Expense InterestExpense	146000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	898000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2160000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7562000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4576000	usd
	FBLG	Deemed Dividend DeemedDividend	-2573000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	898000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2160000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7562000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7149000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32719125	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32719125	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28230842	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28230842	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31926444	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31926444	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28230842	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28230842	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1253000	usd
CY2024Q1	FBLG	Stock Issued During Period Value Preferred Stock StockIssuedDuringPeriodValuePreferredStock	45000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2819000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	480000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8460000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-3863000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	578000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	898000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-2387000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3996000	usd
CY2023Q1	FBLG	Stock Issued During Period Value Sale Of Preferred Stock Net Of Direct Costs StockIssuedDuringPeriodValueSaleOfPreferredStockNetOfDirectCosts	4889000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4286000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	2573000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	448000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2415000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	639000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	639000	usd
CY2023Q2	FBLG	Stock Issued During Period Value Sale Of Preferred Stock Net Of Direct Costs StockIssuedDuringPeriodValueSaleOfPreferredStockNetOfDirectCosts	10056000	usd
CY2023Q2	FBLG	Stock Issued During Period Value Sale Of Preferred Stock One Net Of Direct Costs StockIssuedDuringPeriodValueSaleOfPreferredStockOneNetOfDirectCosts	253000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2117000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	448000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2160000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2160000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	11353000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	11353000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7562000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4576000	usd
	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument	-2422000	usd
	FBLG	Fair Value Adjustment Of Forward Contract Liability FairValueAdjustmentOfForwardContractLiability	1500000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1103000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	896000	usd
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	72000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	81000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	205000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	192000	usd
	us-gaap	Depreciation Depreciation	72000	usd
	us-gaap	Depreciation Depreciation	3000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	482000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	39000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	284000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-236000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	174000	usd
	FBLG	Increase Decrease In In Commitment Fee Payable IncreaseDecreaseInInCommitmentFeePayable	1941000	usd
	FBLG	Increase Decrease In Payable To Parent IncreaseDecreaseInPayableToParent	-141000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-198000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-180000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6222000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3661000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	74000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	80000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-74000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-80000	usd
	FBLG	Rofn Agreement Payments To Parent RofnAgreementPaymentsToParent	2645000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	300000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	574000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	287000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	14945000	usd
	FBLG	Proceeds From Issuance Of Preferred Stock And Preference Stock1 ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1	253000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2819000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3106000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12853000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3190000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9112000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9163000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2266000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5973000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11378000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4000	usd
	FBLG	Issuance Of Series B Preferred Stock For Conversion Of Notes And Accrued Interest IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest	5532000	usd
	FBLG	Reclassification Of Derivative Liability For Conversion Of Notes To Series B Preferred Stock ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock	538000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31919000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5973000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2819000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-4 shares
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zbkPxeoW00c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zLZNz0w1znH8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Unaudited Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Unaudited Condensed Financial Statements and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date of the Unaudited Condensed Financial Statements; therefore, actual results could differ from those estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zw8PjN6hMkIh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zYkyuWXshVQb">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit of $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_pn3d_c20240630_zEHIu6gIsXb8" title="Federally insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2024Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	5510000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	898000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2160000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7562000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4576000	usd
	FBLG	Deemed Dividend DeemedDividend	-2573000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	898000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2160000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7562000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7149000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32719125	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32719125	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28230842	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28230842	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31926444	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31926444	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28230842	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28230842	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2024Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3000000	shares
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	5600000	usd
CY2022Q4	FBLG	Capital Stock In Excess CapitalStockInExcess	10000000	usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	300000	usd
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	60070	shares
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	918000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	844000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	119000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	799000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	797000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	37000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	2000	usd
	us-gaap	Depreciation Depreciation	72000	usd
	us-gaap	Depreciation Depreciation	3000	usd
CY2023Q4	FBLG	Liability Instrument LiabilityInstrument	7236000	usd
CY2024Q1	FBLG	Warrant Liability WarrantLiability	20963000	usd
CY2024Q2	FBLG	Warrant Liability WarrantLiability	4814000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	5510000	usd
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	5510000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1500000	usd
CY2024Q2	FBLG	Warrant Liability WarrantLiability	4814000	usd
CY2024Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6314000	usd
CY2023Q4	FBLG	Liability Instrument Fair Value LiabilityInstrumentFairValue	7236000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	7236000	usd
CY2024Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	51250	shares
CY2022	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	168000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000	shares
	FBLG	Description Of Share Subscription Agreement DescriptionOfShareSubscriptionAgreement	The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the Company’s common stock over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average price per share over that same period. A 1% fee was due to the investors if the Company were sold in a private sale transaction rather than completing a public listing of its shares.
CY2024Q1	FBLG	Commitment Fee Payable CommitmentFeePayable	2000000	usd
CY2024Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	1941000	usd
CY2024Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3000000	shares
CY2023Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2023Q2	us-gaap	Payments For Rent PaymentsForRent	6000	usd
CY2023Q3	us-gaap	Payments For Rent PaymentsForRent	7000	usd
CY2024Q1	us-gaap	Payments For Rent PaymentsForRent	8000	usd
	us-gaap	Payments For Rent PaymentsForRent	311000	usd
	us-gaap	Payments For Rent PaymentsForRent	359000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	218000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	488000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	544000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	509000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1759000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	210000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1549000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	382000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1167000	usd
	FBLG	Payments For Equity Investments PaymentsForEquityInvestments	323000	usd
CY2022	FBLG	Payments For Equity Investments PaymentsForEquityInvestments	2265000	usd
CY2022	FBLG	Percentage Of Gross Proceeds From Equity Investments PercentageOfGrossProceedsFromEquityInvestments	0.15	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	101250	shares
CY2022Q3	us-gaap	Share Price SharePrice	3.28
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3689750	shares
CY2023Q1	us-gaap	Share Price SharePrice	2.28
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2500	shares
CY2023Q3	us-gaap	Share Price SharePrice	3.28
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	216875	shares
CY2024Q1	us-gaap	Share Price SharePrice	13.00
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6875	shares
CY2024Q2	us-gaap	Share Price SharePrice	6.73
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8487750	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8711500	shares
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	579000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	448000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1058000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	896000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6359000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.042	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.043	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0389	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.97	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.01	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.90	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.63

Files In Submission

Name	View Source	Status
fblg-20240630_cal.xml	Edgar Link	unprocessable
0001493152-24-030603-index-headers.html	Edgar Link	pending
0001493152-24-030603-index.html	Edgar Link	pending
0001493152-24-030603.txt	Edgar Link	pending
0001493152-24-030603-xbrl.zip	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex10-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
fblg-20240630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
fblg-20240630_def.xml	Edgar Link	unprocessable
fblg-20240630_lab.xml	Edgar Link	unprocessable
fblg-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBLG
FibroBiologics, Inc. Stock $fblg

2024 Q3 Form 10-Q Financial Statement

#000149315224030603 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBLG FibroBiologics, Inc. Stock $fblg

2024 Q3 Form 10-Q Financial Statement

#000149315224030603 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBLG
FibroBiologics, Inc. Stock $fblg